Ensitrelvir Reduces COVID-19 Risk for Contacts
Why this is here: Participants receiving ensitrelvir experienced a 64% reduction in the risk of developing COVID-19 compared to those receiving a placebo.
Japanese researchers report ensitrelvir cuts COVID-19 infection risk by roughly 64% in household contacts. The phase three trial involved 500 participants in Japan who received either ensitrelvir or a placebo within three days of a household member developing COVID-19 symptoms. Participants took the medication orally for five days.
The study shows 28 of 250 people taking ensitrelvir developed COVID-19. In comparison, 76 of 250 people taking the placebo contracted the virus. Researchers observed no serious adverse effects from the drug.
The trial did not assess ensitrelvir’s effectiveness against all COVID-19 variants. Further research needs to explore the drug's impact on different strains and in diverse populations beyond Japan. The team continues to investigate antiviral options for managing COVID-19.
Surfaced by the Thriving lens — one of the vital signs ovr.news reads.
How we evaluated this
AI summary
read the original for the full story — Read on medicalxpress.com . How we work →